Company registration number 01732557 (England and Wales)
SHERWOOD LABORATORIES LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
SHERWOOD LABORATORIES LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 11
SHERWOOD LABORATORIES LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
322
403
Tangible assets
5
83,189
108,619
Investments
6
27,000
27,000
110,511
136,022
Current assets
Stocks
270,929
328,094
Debtors
7
771,205
166,001
Cash at bank and in hand
852,295
1,238,154
1,894,429
1,732,249
Creditors: amounts falling due within one year
8
(261,906)
(331,799)
Net current assets
1,632,523
1,400,450
Total assets less current liabilities
1,743,034
1,536,472
Creditors: amounts falling due after more than one year
9
(13,171)
(23,333)
Deferred tax provision
(4,712)
(23,840)
Net assets
1,725,151
1,489,299
Capital and reserves
Called up share capital
10
7,803
7,803
Capital redemption reserve
42,202
42,202
Profit and loss reserves
1,675,146
1,439,294
Total equity
1,725,151
1,489,299

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 11 June 2026 and are signed on its behalf by:
M J Bagge
K D Bagley
Director
Director
Company registration number 01732557 (England and Wales)
SHERWOOD LABORATORIES LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Share capital
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2024
7,803
42,202
1,232,682
1,282,687
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
307,580
307,580
Dividends
-
-
(100,968)
(100,968)
Balance at 31 December 2024
7,803
42,202
1,439,294
1,489,299
Year ended 31 December 2025:
Profit and total comprehensive income
-
-
248,594
248,594
Dividends
-
-
(12,742)
(12,742)
Balance at 31 December 2025
7,803
42,202
1,675,146
1,725,151
SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

Sherwood Laboratories Limited is a private company limited by shares incorporated in England and Wales. The registered office is Sherwood Laboratories Ltd, Brunel Drive, Newark, NG24 2EG.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for 12 months from the signing date. Thus the directors continue to adopt the going concern basis of accounting in preparingtrue the financial statements.

1.3
Turnover

Revenue comprises sales of goods to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts.

 

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 

Where payments are received from customers in advance the amounts are recorded in deferred income and included within creditors falling due within one year.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
20% reducing balance
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant, machinery and equipment
25% reducing balance
Fixtures and fittings
20% reducing balance
Computer equipment
20% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial instruments and include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances and amounts due from fellow group companies, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual

arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade and other creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the fair value of proceeds received, net of

transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Taxation

The tax expense represents the sum of the current tax expense and deferred tax expense. Current tax assets are recognised when tax paid exceeds the tax payable.

 

Current and deferred tax is charged or credited to profit or loss, except when it relates to items charged or credited to other comprehensive income or equity, when the tax follows the transaction or event it relates to and is also charged or credited to other comprehensive income, or equity.

SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Current tax

Current tax assets and current tax liabilities and deferred tax assets and deferred tax liabilities are offset, if and only if, there is a legally enforceable right to set off the amounts and the entity intends either to settle on the net basis or to realise the asset and settle the liability simultaneously.

 

Current tax is based on taxable profit for the year. Current tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted by the reporting date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. Timing differences are differences between the company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements.

 

Deferred tax is measured at the average tax rates that are expected to apply in the periods in which timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred tax is measured on a non-discounted basis.

 

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
19
21
4
Intangible fixed assets
Other
£
Cost
At 1 January 2025 and 31 December 2025
7,700
Amortisation and impairment
At 1 January 2025
7,297
Amortisation charged for the year
81
At 31 December 2025
7,378
Carrying amount
At 31 December 2025
322
At 31 December 2024
403
SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
5
Tangible fixed assets
Plant, machinery and equipment
Fixtures and fittings
Computer equipment
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 January 2025
1,444,860
68,202
122,930
141,861
1,777,853
Additions
4,165
-
0
2,179
-
0
6,344
Disposals
-
0
-
0
-
0
(35,777)
(35,777)
At 31 December 2025
1,449,025
68,202
125,109
106,084
1,748,420
Depreciation and impairment
At 1 January 2025
1,418,602
66,905
112,387
71,340
1,669,234
Depreciation charged in the year
6,834
260
2,572
16,388
26,054
Eliminated in respect of disposals
-
0
-
0
-
0
(30,057)
(30,057)
At 31 December 2025
1,425,436
67,165
114,959
57,671
1,665,231
Carrying amount
At 31 December 2025
23,589
1,037
10,150
48,413
83,189
At 31 December 2024
26,258
1,297
10,543
70,521
108,619
6
Fixed asset investments
2025
2024
£
£
Shares in investment
27,000
27,000
7
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
157,969
97,045
Amounts owed by group undertakings
592,056
51,367
Prepayments
21,180
17,589
771,205
166,001
SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
8
Creditors: amounts falling due within one year
2025
2024
£
£
Obligations under finance leases
10,000
10,000
Trade creditors
23,548
25,936
Amounts owed to group undertakings
36,453
-
0
Corporation tax
-
0
86,755
Other taxation and social security
157,312
182,187
Other creditors
1,600
8,800
Accruals and deferred income
32,993
18,121
261,906
331,799
9
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Obligations under finance leases
13,171
23,333

Obligations under hire purchase contracts are secured over the assets to which they relate.

10
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
7,803
7,803
7,803
7,803
11
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
34,400
2,625
12
Related party transactions

The company has taken advantage of the exemption provided by FRS102 Section 33, not to disclose transactions and outstanding balances with its fellow 100% directly or indirectly controlled companies within the group.

SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
13
Directors' transactions

As at the year end, the balance owed to the directors was £1,600 (2024: £8,800) in respect of their directors loan accounts. This balance is unsecured, interest-free and has no fixed repayment date.

 

The company was related to Sherwood Laboratories Small Self Administered Scheme during the year by virtue of D Bagley, the father of G D Bagley, being a trustee and member of the scheme. During the year the company paid rent of £7,292 (2024: £29,167) to the scheme while G D Bagley was still a director of the company.

 

During the year the company received dividends of £3,000 (2024: £3,000) from a company with common directors. As at the year end there were no amounts due to or from the company. 

 

14
Parent company

The immediate parent company is Wrates Bagley Limited, a company registered in England and Wales with a registered office of Plot 41 Brunel Drive, Newark, Nottinghamshire, NG24 2EG.

 

On 2 April 2025 EPG UK Holdco Ltd acquired 100% of the share capital in Wrates Bagley Limited.

 

The smallest group which draws up consolidated financial statements including Sherwood Laboratories Limited, is that headed by EPG UK Holdco Ltd. Copies of the group financial statements are available from its registered office C/O Sherwood Laboratories Ltd, Brunel Drive, Newark, Nottinghamshire, England, NG24 2EG.

15
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is qualified and includes the following:

Qualified opinion

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, the financial statements:

SHERWOOD LABORATORIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
15
Audit report information
(Continued)
- 11 -

Basis for qualified opinion

The financial statements of the company were not audited at 31 December 2024 and thus no auditors or other independent third party attended the stock take at this date and it was not possible to gain evidence of stock quantities and valuation of the opening stock held at that date using alternative procedures. Consequently we were unable to determine whether any adjustments to the stock value of £328,094 were necessary or whether there were any consequential effects on the cost of sales, profit for the year and retained earnings for the year ended 31 December 2024.

 

As opening balances form part of the current year’s financial statements we were unable to determine whether any adjustment to this amount was necessary.

Our opinion on the financial statements for the year ended 31 December 2025 is therefore qualified in respect of this matter.

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other matters which we are required to address
The comparative figures were not audited.
Senior Statutory Auditor:
Vinay Bahl
Statutory Auditor:
Shaw Gibbs (Audit) Limited
Date of audit report:
12 June 2026
2025-12-312025-01-01falsefalsefalse12 June 2026CCH SoftwareCCH Accounts Production 2026.200No description of principal activityM J BaggeG D BagleyM C WrateJ O M JonssonK D BagleyS C WrateS C Wrate017325572025-01-012025-12-31017325572025-12-31017325572024-12-3101732557core:IntangibleAssetsOtherThanGoodwill2025-12-3101732557core:IntangibleAssetsOtherThanGoodwill2024-12-3101732557core:PlantMachinery2025-12-3101732557core:FurnitureFittings2025-12-3101732557core:ComputerEquipment2025-12-3101732557core:MotorVehicles2025-12-3101732557core:PlantMachinery2024-12-3101732557core:FurnitureFittings2024-12-3101732557core:ComputerEquipment2024-12-3101732557core:MotorVehicles2024-12-3101732557core:WithinOneYear2025-12-3101732557core:WithinOneYear2024-12-3101732557core:AfterOneYear2025-12-3101732557core:AfterOneYear2024-12-3101732557core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3101732557core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3101732557core:ShareCapital2025-12-3101732557core:ShareCapital2024-12-3101732557core:CapitalRedemptionReserve2025-12-3101732557core:CapitalRedemptionReserve2024-12-3101732557core:RetainedEarningsAccumulatedLosses2025-12-3101732557core:RetainedEarningsAccumulatedLosses2024-12-3101732557core:ShareCapital2023-12-3101732557core:CapitalRedemptionReserve2023-12-3101732557core:RetainedEarningsAccumulatedLosses2023-12-3101732557core:ShareCapitalOrdinaryShareClass12025-12-3101732557core:ShareCapitalOrdinaryShareClass12024-12-3101732557bus:Director12025-01-012025-12-3101732557bus:Director52025-01-012025-12-3101732557core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31017325572024-01-012024-12-3101732557core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3101732557core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3101732557core:ComputerSoftware2025-01-012025-12-3101732557core:PlantMachinery2025-01-012025-12-3101732557core:FurnitureFittings2025-01-012025-12-3101732557core:ComputerEquipment2025-01-012025-12-3101732557core:MotorVehicles2025-01-012025-12-3101732557core:IntangibleAssetsOtherThanGoodwill2024-12-3101732557core:PlantMachinery2024-12-3101732557core:FurnitureFittings2024-12-3101732557core:ComputerEquipment2024-12-3101732557core:MotorVehicles2024-12-31017325572024-12-3101732557core:CurrentFinancialInstruments2025-12-3101732557core:CurrentFinancialInstruments2024-12-3101732557core:Non-currentFinancialInstrumentscore:AfterOneYear2025-12-3101732557core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3101732557bus:OrdinaryShareClass12025-01-012025-12-3101732557bus:OrdinaryShareClass12025-12-3101732557bus:OrdinaryShareClass12024-12-3101732557bus:PrivateLimitedCompanyLtd2025-01-012025-12-3101732557bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3101732557bus:FRS1022025-01-012025-12-3101732557bus:Audited2025-01-012025-12-3101732557bus:Director22025-01-012025-12-3101732557bus:Director32025-01-012025-12-3101732557bus:Director42025-01-012025-12-3101732557bus:Director62025-01-012025-12-3101732557bus:Director72025-01-012025-12-3101732557bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP